Stephen Broderick
Johns Hopkins University · 166 works · 12,716 citations · h-index 39
Top works
- Somatic mutations affect key pathways in lung adenocarcinoma
- Characterizing the cancer genome in lung adenocarcinoma
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors
- Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma
- Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer
- Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4
- Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancer
- Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
- COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network
- LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression
- Intraoperative conversion from video-assisted thoracoscopic surgery lobectomy to open thoracotomy: A study of causes and implications
- Epigenetic therapy inhibits metastases by disrupting premetastatic niches
- COVID-19 Guidance for Triage of Operations for Thoracic Malignancies: A Consensus Statement From Thoracic Surgery Outcomes Research Network
- Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial
- Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
- Stereotactic Body Radiotherapy for Early-Stage Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline
- Pathologic Upstaging in Patients Undergoing Resection for Stage I Non-Small Cell Lung Cancer: Are There Modifiable Predictors?
- Hemothorax